[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-participants-study\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-participants-study":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,65,88,120,142,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100623810","phase-1-study-of-bw-50218-in-healthy-participants-100623810",false,"NCT07401472","Study of BW-50218 in Healthy Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants","Inclusion Criteria:\n\n* Capable of providing written informed consent and complying with all study procedures for the duration of the study.\n* Body weight and body mass index (BMI) within a range considered appropriate for study participation by the investigator.\n* Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception.\n* Male participants with partners of childbearing potential must agree to use effective contraception.\n\nExclusion Criteria:\n\n* Any medical condition, recent illness, or laboratory result that, in the investigator's opinion, may increase risk or interfere with participation in the study.\n* Recent hospitalization or a significant acute medical event.\n* History of cancer or any long-term medical condition that the study doctor considers clinically relevant.\n* Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1.\n* Positive test for hepatitis B, hepatitis C, or HIV.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants",[28],"Healthy Participants Study","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"2026-03-12",{"date":37,"type":22},"2027-06-30",{"name":39,"class":40},"Shanghai Argo Biopharmaceutical Co., Ltd.","INDUSTRY",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100643355","phase-1-healthy-participants-randomized-double-blind-placebo-controlled-phase--100643355","NCT07640438","Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ","A Phase Ⅰ Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of BY002 in Healthy Participants","Inclusion Criteria:\n\n* 1\\. Male or female aged ≥18 years at the time of signing the Informed Consent Form (ICF).\n\n  2\\. At screening, body mass index (BMI) between 18 and 30 kg\u002Fm² (inclusive), with weight ≥50.0 kg for males and ≥45.0 kg for females.\n\n  3\\. Good health status determined by screening examinations. Good health status is defined as: absence of clinically relevant abnormalities or psychiatric diseases that, in the investigator's judgment, could compromise participant safety, affect the scientific validity of the study, expose the participant to unacceptable risk, or interfere with their compliance with study procedures and restrictions.\n\n  4\\. Male participants and their partners of childbearing potential must agree to use highly effective contraception during the study and for at least 12 weeks after the last dose. Male participants must refrain from donating sperm during this period. Female participants must not be pregnant or lactating. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and be willing to use highly effective contraception throughout the study and for at least 12 weeks after the last dose. Female participants must avoid donating eggs during this period.\n\n  5\\. Participants who, after capsaicin challenge during screening, meet the criteria specified in the Capsaicin Challenge Test Operating Manual (applicable only to participants undergoing the capsaicin challenge test).\n\n  6\\. Provide written informed consent before any study-related procedures are performed.\n\nExclusion Criteria:\n\n* 1\\. Individuals with a history or current presence of clinically significant cardiovascular (e.g., hypertension), pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, musculoskeletal, rheumatologic, psychiatric, systemic, ocular, reproductive, otorhinolaryngological, dermatological, or infectious diseases, or acute disease signs, unless deemed not clinically significant by the investigator and sponsor.\n\n  2\\. Individuals who have donated blood (≥400 mL) or experienced significant blood loss (≥400 mL), donated ≥2 units of blood components, or received a blood transfusion within 2 months prior to the first dose of investigational drug; or who plan to donate blood during the study.\n\n  3\\. Individuals with allergic constitution (defined as a clear history of allergy to two or more drugs, or to two or more common foods, or to common inhaled\u002Fcontact irritants such as pollen, dust mites, pet dander, mold, etc.), or a known history of allergic reactions to any therapeutic protein drugs (including monoclonal antibodies, fusion proteins, recombinant enzymes, cytokines, peptide hormones, blood products, vaccines, etc.).\n\n  4\\. Participants who are known to be allergic to any component of the investigational drug product or to capsaicin (applicable only to participants undergoing the capsaicin challenge test), or who have other contraindications.\n\n  5\\. Alcohol abuse or frequent alcohol consumption within 6 months prior to screening, defined as weekly alcohol intake exceeding 14 units (1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine), or unwillingness to abstain from alcohol and any alcohol-containing products during the study; or a positive alcohol breath test.\n\n  6\\. History of drug abuse within 12 months prior to screening, or positive urine drug screen result.\n\n  7\\. Smokers (defined as consuming more than 5 cigarettes or equivalent products per week), or those who cannot discontinue the use of any tobacco products during the study period.\n\n  8\\. The investigator determines that the participant's skin characteristics are unsuitable for capsaicin skin challenge (applicable only to participants undergoing the capsaicin challenge test).\n\n  9\\. Participants for whom venous blood collection is difficult.\n\n  10\\. Individuals who, as judged by the investigator, have clinically significant abnormalities in physical examination, vital signs, ECG, clinical laboratory tests (hematology, blood biochemistry, urinalysis, coagulation function), or chest X-ray at screening.\n\n  11\\. Individuals with a QT interval corrected using Fridericia's formula (QTcF) \\>450 ms for male participants or \\>470 ms for female participants on the screening electrocardiogram (ECG).\n\n  12\\. Positive result in any of the following tests: Hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV) antibody, anti-human immunodeficiency virus antibody (anti-HIV Ab), and specific antibody to Treponema pallidum (TP-Ab).\n\n  13\\. Individuals who have used any prescription medication, over-the-counter (OTC) drugs, traditional Chinese patent medicines, Chinese herbal medicines, vitamins, or dietary supplements within 14 days prior to the first dose or within 5 elimination half-lives or pharmacodynamic half-lives (whichever is longer) that may interfere with the study assessments.\n\n  14\\. Receipt of any vaccine within 2 weeks prior to the first dose of the investigational drug.\n\n  15\\. Individuals who have enrolled in or participated in any clinical trial containing investigational drugs or other medical research within 1 month prior to the first dose, or within 5 elimination half-lives (whichever is longer).\n\n  16\\. Individuals deemed by the investigator to be likely noncompliant during the study period, or unable to cooperate due to language barriers or intellectual disability, or otherwise unsuitable for participation in the trial.",{"count":50,"type":22},104,[25],"The objective of this clinical trial is to evaluate the safety and tolerability of BY002 in healthy subjects.\n\nInvestigators will compare BY002 to a placebo (a pharmacologically inactive substance) to assess the safety and tolerability of BY002 in healthy subjects.\n\nParticipants will undergo:\n\n1. Single\u002Fmultiple subcutaneous (SC) administrations of BY002\u002Fplacebo\n2. A 7-day safety follow-up period following the last dose",[28],"2026-06-05",{"date":56,"type":33},"2026-06-10",{"date":58,"type":33},"2026-06-01",{"date":60,"type":22},"2027-04-30",{"name":62,"class":63},"First Affiliated Hospital of Zhejiang University","OTHER",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":64},"100635567","phase-1-a-trial-to-assess-safety-tolerability-and-pharmacokinetics-of-an01-inhalation-powder-in-healthy-participants-100635567","NCT07554365","A Trial to Assess Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants","A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants","Inclusion Criteria:\n\n1. Healthy adults ≥18 and ≤60 years (inclusive).\n2. Body Mass Index (BMI) ≥18 and ≤32 kg\u002Fm2 (inclusive).\n3. Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, spirometry, and electrocardiogram (ECG).\n4. Non-smokers or former smokers who have quit for ≥2 years with a prior smoking history of \\\u003C5 pack-years (pack-years defined as = cigarettes per day × years smoked; 1 pack = 20 cigarettes).\n5. Female participants must be non-pregnant and non-lactating, and, surgically sterile, use highly effective contraceptive methods from Screening until at least 30 days after the last dose of study drug, or post-menopausal for ≥12 months.\n6. Male participants must be surgically sterile, abstinent, or their partner must be surgically sterile, or if engaged in sexual relations with a woman of childbearing potential (WOCBP), the male participant and his partner must use an acceptable, highly effective contraceptive method from Screening until at least 90 days after the last dose of study drug.\n\nExclusion Criteria:\n\n1. History of clinically significant (as per Investigator's judgment) upper respiratory disease or history of any significant pulmonary disease including, but not limited to, asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and history of previous tuberculosis exposure with positive interferon gold test (without actual infection).\n2. Participants with any history of, or active, clinically significant disease (e.g., cardiovascular disease, chronic liver disease, psychiatric medical history, renal disease) that could interfere with the interpretation of the study results or compromise the health of the participant based on the judgment of the Investigator.\n3. Administration of vaccines\u002Fimmunizations and\u002For boosters within 8 days prior to first dosing or if planned during the study.\n4. Any history of active infection at the time of Screening and\u002For within 28 days prior to first dosing.\n5. Any prior participation in a study with an investigational drug or device involving a biological targeted therapy, where final administration of the investigational drug or utilization of the device occurred within 24 weeks prior to first dosing.\n6. History of migraine headaches requiring prescription medication or occurring more than 2-4 times per month within the past 6 months.\n7. Use of non-tobacco vaping within 12 months prior to Screening.\n8. Use of any tobacco and\u002For inhaled marijuana product within 2 years prior to Screening.","60 Years",{"count":74,"type":22},24,[25],"AN01 is a selective small-molecule dual inhibitor of phosphodiesterase 3 and 4 (PDE3\u002F4).\n\nAs a potential new therapy for COPD, AN01 is expected to serve either as a monotherapy for COPD or as adjunctive therapy to current inhaled standard treatments, potentially generating synergistic complementary effects in patients requiring additional therapeutic options.\n\nThe primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of AN01 in healthy participants.",[78,28],"Healthy Volunteer","2026-05-26",{"date":81,"type":33},"2026-05-28",{"date":83,"type":33},"2026-05-13",{"date":85,"type":22},"2026-06",{"name":87,"class":40},"AirNexis Therapeutics, Inc.",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":16,"sex":17,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100632715","phase-1-study-to-determine-the-comparative-pharmacodynamics-of-enoxaparin-sodium-biosimilar-with-that-from-clexane-100632715","NCT07517289","Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar With That From Clexane","Study Name: (SPRING) Study of Pharmacodynamics and Relative Bioavailability of an Invented National Generic Enoxaparin","Inclusion Criteria:\n\n* Healthy male and female participants aged 21 to 55 years at the time of the first dose administration.\n* Body Mass Index (BMI) between 18.5 and 30 kg\u002Fm², and body weight of at least 45 kg.\n* Participants must have vital signs within the normal range, as defined below, measured at pre-dose:\n* Blood Pressure: Systolic 100-130 mmHg, Diastolic 70-90 mmHg.\n* Pulse Rate: 60-100 beats per minute (bpm).\n* Body Temperature: 36.1-37.2\n\nExclusion Criteria:\n\n* Hypersensitivity to Enoxaparin or any of the formulation excipients\n* Contraindication to enoxaparin or related group of drugs, which includes but not limited to significant bleeding disorders, thrombocytopenia, blood-clothing disorders, and increased risk of bleeding.\n* History or presence of any medical condition or disease according to the opinion of the principal Investigator\n* History or presence of significant alcoholism or drug abuse in the past one year.\n* History or presence of heavy smoking (≥10 cigarettes or consumption of tobacco products and refusal to restrain from smoking or consumption of tobacco products for 48.00 hours before dosing until checkout of the study).\n* History or presence of significant renal, hepatobiliary, or liver impairment; a medical or familial history of seizures; significant asthma, urticaria, or other allergic reactions; or any other significant medical condition as determined by the Principal Investigator or their delegate.\n* History of difficulty with donating blood or difficulty in accessibility of veins\n* Use of any prescribed medication, OTC medicines or herbal medicines during the last two weeks preceding the first dosing\n* Participants who have any food allergy, intolerance, restriction, or special diet during the four weeks before screening\n* Participation in a drug research study within the past 2 months planned day of first dose administration\n* Donation of blood in the past 2 months before screening\n* Refusal to abstain from food (fasting) for at least ten hours before dosing\n* Refusal to abstain from alcohol or methylxanthine-containing beverages\n* Participants with a positive test for HBs-Ag, HIV-Ab, or HCV-Ab\n* Participant with a positive drug abuse test in urine at screening or at the time of check-in\n* Participant with abnormal baseline coagulation parameters, such as prolonged PT (if greater than 1.2 to 1.5 times the ULN of approximately 11 to 15 seconds), aPTT (if greater than 1.5 to 2.5 times the ULN of 25 to 40 seconds), or INR values (is above 1.4) outside the normal reference range.\n\nThis is to minimize bleeding risk and confounding effects on study outcomes.","21 Years","55 Years",{"count":98,"type":22},26,[25],"An Open-Label, Single-center, Randomized, Single-Dose, Two-Way Crossover Biosimilarity Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar 40mg\u002F0.4ml with that from the Reference IMP, Clexane® (40 mg\u002F0.4ml), Following Single-Dose Administration in Healthy Participants. Test: Enoxaparin Sodium (Enoxaparin Sodium 40mg\u002F0.4ml) manufactured by EIPICO, Egypt. Reference: Clexane (Enoxaparin Sodium 40mg\u002F0.4ml) manufactured by Sanofi Aventis, Egypt. Primary objective:\n\nTo assess biosimilarity between a single dose from the test product versus the reference product in healthy participants\n\nSecondary objective:\n\nTo investigate the safety and tolerability of the formulations. This study is a randomized single-dose, two-way, two-period, two-sequence, crossover biosimilarity study with a washout period of one week after each dosing.A minimum of 21 healthy adult male and female participants from Egyptian population will be enrolled in this study, along with 5 additional participants to account for potential dropouts or withdrawal. 26 Participants plus 1-4 alternates will be admitted to the study. An alternate participant will be dosed by the same sequence as the withdrawn participant only if any participant of the first 26 Participants withdraws before the first study drug administration. Withdrawals after study drug administration will not be replaced. All participants will be healthy adults aged (21-55) years, with a BMI within the accepted range of 18.5-30 kg\u002Fm², and will meet the study's selection criteria.",[28,102],"The Focus of the Study is to Determine the Comparative Pharmacodynamic of Enoxaparin Sodium With That of Clexane in Healthy Human Participants",[104,105,106,107,108,109],"Enoxaparin Sodium","Pharmacodynamics","Clexane","Randomized","Healthy participants","single dose","NOT_YET_RECRUITING","2026-04-01",{"date":113,"type":33},"2026-04-08",{"date":115,"type":22},"2026-04-30",{"date":117,"type":22},"2026-08",{"name":119,"class":40},"Egyptian International Pharmaceutical Industries Co",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":64},"100624226","positive-psychology---based-eml-for-enhancing-well-being-100624226","NCT07406880","Positive Psychology - Based EMl for Enhancing Well-Being","Positive Psychology-Based Ecological Momentary Intervention for Well-Being in College Students: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants in our study are healthy college students.\n* Have smartphone, and have access to the internet.\n\nExclusion Criteria:\n\n* Unable to use a smartphone.\n* Have significant cognitive impairment that prevents participation in the research",{"count":128,"type":22},354,[130],"NA","This study aims to evaluate the acceptability and effectiveness of a positive psychology-based ecological momentary intervention (EMI) for enhancing well-being in college students. A three-arm randomized controlled trial (RCT) will assess the impact of a dynamic EMI that delivers personalized exercises when participants' real-time affect or well-being scores fall below a predefined threshold, compared to control conditions. Primary outcomes include changes in well-being and mental health, evaluated through a mixed-methods approach combining quantitative measures and qualitative interviews.",[28],"2026-02-06",{"date":135,"type":33},"2026-02-12",{"date":137,"type":22},"2026-02-01",{"date":139,"type":22},"2026-12-30",{"name":141,"class":63},"The Hong Kong Polytechnic University",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":16,"sex":17,"minAge":72,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":4},"100599355","impact-of-digital-oral-health-educational-program-on-a-group-of-geriatrics-oral-health-and-quality-of-life-compared-to-standard-oral-health-educational-program-in-egypt-100599355","NCT07083414","Impact of Digital Oral Health Educational Program on a Group of Geriatrics Oral Health and Quality of Life Compared to Standard Oral Health Educational Program in Egypt","Impact of Digital Oral Health Educational Program on a Group of Geriatrics Oral Health and Quality of Life Compared to Standard Oral Health Educational Program in Egypt: a Cluster Randomized Control Trial","Inclusion Criteria:\n\n* Old age population above years old.\n* Participants who is willing to confirm consent for the educational program and assessment.\n* Participants without disability that interfere during communication.\n\nExclusion Criteria:\n\n* Individuals with palliative care and rehabilitation ward, presence of mental disorder, had dangerous communicable disease.\n* Participants who refused to participate.",{"count":150,"type":22},40,[130],"The aim of the study is to evaluate the impact of a digital oral health education program on the oral health status and quality of life for geriatric populations compared to standard oral health education in Egypt.",[154,28],"Oral Health Self-efficacy",[156,157,158],"Educational program","Oral health program","Quality of life","2025-07-23",{"date":161,"type":33},"2025-07-28",{"date":163,"type":22},"2025-12-01",{"date":165,"type":22},"2026-06-15",{"name":167,"class":63},"Cairo University",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":64},"100580906","act-based-emi-in-college-students-100580906","NCT06843395","ACT-based EMI in College Students","Assessing the Feasibility, Acceptability and Effectiveness of an Transdiagnostic Acceptance and Commitment Therapy-based Ecological Momentary Intervention in College Students: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants in our study are healthy college students\n* have smartphone, and have access to the internet\n\nExclusion Criteria:\n\n* currently participating in another research\n* have significant cognitive impairment that prevents participation in the research",{"count":21,"type":22},[130],"This study aims to evaluate the acceptability and effectiveness of a transdiagnostic, Acceptance and Commitment Therapy (ACT)-based ecological momentary intervention (EMI) among college students. A mixed-methods pilot randomized controlled trial (RCT) will be conducted to assess its impact on psychological flexibility, well-being and mental health outcomes.",[28],"2025-03-06",{"date":181,"type":33},"2025-03-11",{"date":183,"type":22},"2025-04-15",{"date":185,"type":22},"2025-12-31",{"name":141,"class":63}]